Skip to main content
. 2015 Sep 10;6(31):31927–31943. doi: 10.18632/oncotarget.5578

Figure 2. Icaritin suppresses HCICs.

Figure 2

(A, B). PLC/PRF/5 and Huh7 cells were treated with the indicated concentrations of Icaritin, Cisplatin (10μg/ml) or DMSO for two days and then the 7-AAD negative cells (living cells) were assayed with EpCAM flow cytometric analysis. (C, D). PLC/PRF/5 and Huh7 cells were treated with Icaritin, Cisplatin or DMSO for two days, washed and maintained in normal medium for another one day for recovering. The 7-AAD negative cells were seeded in low attachment dishes in the absence of drugs to form hepatospheres for five days. The number of the hepatoshperes was counted. Columns, mean (n = 3); bars, SEM. (E, F). PLC/PRF/5 and Huh7 cells were treated with Icaritin (10 μM), Cisplatin (10 μg/ml) or DMSO for two days, washed and cells were cultured for another one day for recovering, 5×105 of 7-AAD negative cells were injected subcutaneously in each of NOD/SCID mice in the absence of drugs. Points, mean (n=5); bars, SEM. *P< 0.05; **P< 0.01; ***P<0.001; ICT, Icaritin; CIS, Cisplatin.